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Treatment of hyperphosphatemia with sevelamer hydrochlo- cacy of sevelamer in lowering serum phosphorus in he-
ride in hemodialysis patients: A comparison with calcium ace- modialysis patients.
tate.
Background. Sevelamer hydrochloride is a recently ap-
proved calcium- and aluminium-free phosphate binder. A ran- METHODSdomized study comparing sevelamer and calcium acetate was
performed to assess the control of hyperphosphatemia in he- Patients
modialysis patients. The study included male and female hemodialysis pa-Methods. Administration of phosphate binders was discon-
tients aged 18 years or older who were treated for attinued during a two-week washout period. The patients were
then randomized to receive sevelamer or calcium acetate. The least three months with hemodialysis three times per
laboratory tests were performed monthly for 34 weeks. week. Inclusion criteria required calcium-based phos-
Results. There was a statistically significant decrease of se- phate binders and vitamin D therapy at stable doses for
rum phosphorus in both sevelamer and calcium acetate treat-
at least one month. Furthermore, subjects were excludedments. In addition, sevelamer improved the lipid profile.
from participation if they had any unstable medical con-Conclusion. This study confirms that sevelamer is effective
at lowering serum phosphorus in hemodialysis patients and dition, including poorly controlled diabetes mellitus, hy-
that it has several striking properties that could be beneficial pertension, or any gastrointestinal abnormality.
in atherosclerosis in dialysis patients.
Study design
Patients were chosen and administration of calcium-
Secondary hyperparathyroidism and hyperphosphate-
containing phosphate binder was discontinued during
mia are common complications in end-stage renal dis-
a two-week washout period. Patients who developed a
ease. Treatment usually includes dietary restriction of
serum phosphorus level greater than 6 mg/dL during this
phosphorus, use of carbonate or acetate salts of calcium,
washout were eligible for the study. After the two-weekand often, the administration of vitamin D metabolites
washout phase, subjects were randomized to receive sev-[1, 2, 3]. Calcium salts have become the treatment choice
elamer hydrochloride or calcium acetate. Sevelamer wasfor hyperphosphatemia, although the provision of cal-
supplied in a capsule containing 403 mg (Renagel),cium can lead to hypercalcemia and increase the risk of
while the calcium acetate was supplied as Royen, con-metastatic calcification, particularly in those patients on
taining 500 mg calcium acetate. The beginning medica-calcitriol therapy and patients with low bone turnover
tion dose was determined by the initial level of phospho-rates [1, 3–5].
rus and ranged from 2 to 4 capsules three times a daySevelamer hydrochloride is a recently approved calci-
with meals for sevelamer, to 1 to 4 tablets three timesum- and aluminum-free phosphate binder. In previous
per day with meals for calcium acetate [4, 7]. Sevelamerstudies it effectively controlled serum phosphate in he-
and calcium acetate doses could be increased by onemodialysis patients without developing hypercalcemia [6].
capsule or tablet per meal (three capsules or tabletsA randomized study comparing sevelamer and cal-
per day) every four weeks. Serum levels of phosphorus,cium acetate was therefore performed to assess the effi-
calcium, alkaline phosphatase, parathyroid hormone
(PTH), total cholesterol, HDL-cholesterol, LDL-choles-
Key words: hyperparathyroidism, hemodialysis, hypercholesterolemia. terol, and other laboratory tests were monitored at the
pre-washout period and at weeks 2, 6, 10, 14, 18, 22, 26, 2003 by the International Society of Nephrology
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Table 1. Baseline patients’ characteristics
N 51
Age years 60.415.1
Gender % female 40%
Primary renal disease
Glomerulonephritis 17.5%
Interstitial 15%
Cystic 7.5%
Hypertension 15%
DM 15%
Unknown 25%
Others 5%
Length of dialysis months 56.948.7
Previous phosphate binders
Calcium acetate 79%
Calcium carbonate 21%
Dialysate calcium mEq/L
2.5 79%
3.0 21%
Fig. 1. The trends over time in phosphorus, calcium, and calcium xParathyroidectomy 10%
phosphorus product.Vitamin D metabolites 70%
Kt/V 1.160.15
Serum albumine 3.860.41
Cholesterol-lowering agents 11.7%
ing calcium acetate treatment. The incidence of diarrhea,
constipation, and other minimal adverse events was not
statistically different between groups (P  0.2). In the
30, and 34 during the treatment period. Laboratory tests sevelamer group, there was one patient with a gastric
were drawn before the mid-week dialysis session. bezoar who dropped out of the study.
Statistical analysis Dosage and dietary intake
Continuous variables were expressed as mean values  For sevelamer, the mean dose given was 4.09 g/day,
SD. Baseline characteristics were compared between the and for calcium acetate, the mean dose given was 3.9 g/
two groups of patients using a Fisher exact test for cate- day. Dietary intake of calcium, phosphorus, and vitamin
gorical variables and a Wilcoxon signed rank test for D metabolites remained relatively stable throughout the
continuous variables. The effect of treatment was ana- study and was equivalent between groups.
lyzed by measuring the change from the end of the wash-
Serum phosphorus, calcium, alkaline phosphatase, andout period to the determination of the treatment period
intact parathyroid hormoneby a paired t test. An analysis of variance model was
used to assess differences between treatment groups. All Figure 1 shows the changes in serum calcium, serum
statistical analyses were two-tailed with a P value of 0.05 phosphorus, and serum calcium x phosphorus product
required for significance and conducted using a SPSS.10 in both the calcium and sevelamer groups. The mean
software package (SPSS, Inc., Chicago, IL, USA) for serum phosphorus baseline concentration was not statis-
Windows (Microsoft Corporation, Redmond, WA, USA), tically significant before treatment with sevelamer and
and were restricted to subjects who completed the study calcium acetate (8.09  1.6 mg/dL vs. 7.5  1.5 mg/dL;
(N  40, 78%). P  0.5). There was a statistically significant decrease
with both treatments that ranged from 8.09  1.6 mg/dL
to 5.8  1.01 mg/dL; P  0.001 for the sevelamer group,RESULTS
and from 7.5  1.6 mg/dL to 5.9  1.5 mg/dL; P 
Patients 0.005 for the acetate group. The mean change in serum
Sixty-one patients entered the screening period; after phosphorus from baseline to the end of treatment was
a washout period, 51 met the study criteria and were similar between treatments:2.29 0.05 mg/dL (28.3%)
randomized. Forty patients completed the study. Rea- with sevelamer and 1.6  0.1 mg/dL (21.3%) with
sons for withdrawal from the study were: four deaths, calcium acetate. There was not a statistically significant
two kidney transplants, one adverse event (gastric be- increase of serum calcium in either the sevelamer or
zoar), and four cases of lack of compliance. Table 1 calcium acetate therapy (Fig. 1). At least one instance
shows the baseline patients’ characteristic. Sevelamer of hypercalcemia, defined as a serum calcium greater
was well tolerated and the occurrence of side effects was than 11 mg/dL, occurred in 7.1% (N  9) of patients
similar for each treatment. Dyspepsia occurred during with sevelamer treatment, and in 8.9% (N  15) of pa-
tients with calcium acetate treatment (P  0.2). Al-sevelamer treatment in 38% of patients versus 36% dur-
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cium acetate can lead to hypercalcemia in some patients
[1, 3, 5, 14, 15].
We explored the use of a recently approved calcium-
and aluminum-free phosphate binder to lower serum
phosphorus levels in hemodialysis patients and com-
pared it with a standard therapy on a similar population.
This long-term study confirms previous reports, in
which sevelamer is effective at lowering serum phospho-
rus in hemodialysis patients [4, 7, 16–19]. Serum phos-
phorus was significantly reduced by both sevelamer and
calcium acetate treatments, with a corresponding reduc-
tion in the calcium x phosphorus product. This beneficial
effect was sustained over time. The serum phosphorus
Fig. 2. Percent change in total cholesterol, LDL-Cholesterol, HDL- levels achieved at the end of the study was similar to
cholesterol, and triglyceride values.
that observed in other clinical trials. The intact PTH
decreased significantly in both sevelamer and calcium
acetate treatments, but it did not achieve the normal
range in dialysis patients at the end of the study. Perhapsthough the mean baseline calcium x phosphorus product
the reasons for not achieving optimal levels of both se-was higher before treatment with sevelamer than calcium
rum phosphorus and intact PTH were that the dose ofacetate (79.3  17.1 mg2 /dL2 versus 74.6  18.4 mg2/dL2;
sevelamer was sub-optimal (the mean dose given wasP  0.7), the mean change from baseline to the end of
4.09 g/day). The limitation in our patients was the needtreatment was similar between treatments (20.6 mg2/dL2)
for taking a high number of capsules. Recently, the suit-with sevelamer and (15.4 mg2/dL2) with calcium ace-
ability of sevelamer has been improved with new 800 mgtate. Intact PTH levels also decreased with both treat-
tablets.ments, from 479  288 pg/mL to 330  205 pg/mL; P 
Serum calcium was slightly, but not significantly, in-0.04 in the sevelamer group, and from 501  303 pg/mL
creased in sevelamer treatment. Because sevelamer de-to 346  250 pg/mL; P  0.02 in the calcium acetate
creases serum phosphorus with the ability to avoid hy-group. Serum alkaline phosphatase did not increase sig-
percalcemia, we found a subsequent reduction in calciumnificantly with sevelamer treatment (230  78 UI/L to
x phosphorus product. This is probably the most impor-243  65 UI/L; P  0.3) and did not change significantly
tant sevelamer benefit. Block et al [20] recently pointedwith calcium acetate therapy (227  93 UI/L to 226 
out an increase in the relative risk of death with higher120 UI/L; P  0.9).
levels of calcium x phosphorus product. Other authors
have also hypothesized that higher levels of the calcium xSerum lipids
phosphorus product might promote vascular calcification
Figure 2 shows the changes on the lipid profile. For and lead to a decrease in survival related to cardiovascu-
the sevelamer treatment group, the mean change in the lar disease [16]. Coronary-artery calcification is common
total cholesterol was 30.5  13.1 mg/dL (16.5%), and progressive in young adults who are undergoing
LDL-cholesterol was 32.8  14.5 mg/dL (29.9%), dialysis [21, 22]. There is evidence that an effective phos-
and HDL-cholesterol was 8.2  4.6 mg/dL (19.5%). All phate lowering with sevelamer is associated with less
values were statistically significant at P  0.05. For the coronary and aortic calcification [23].
calcium acetate treatment group, the mean levels of total The mild increase in serum alkaline phosphatase dur-
cholesterol, LDL-cholesterol and HDL- cholesterol ing sevelamer treatment was most likely related to its
were not significantly changed. effects on bile acid metabolism [7, 16].
In both treatments, other laboratory values such as tri-
glycerides, serum albumin, total protein, liver enzymes,
CONCLUSIONand bilirubin were not significantly changed.
Sevelamer treatment reduced both serum total choles-
terol and LDL-cholesterol. The 29% reduction in LDL-
DISCUSSION cholesterol by sevelamer treatment is similar to the re-
The efficacy of currently available calcium- or alumi- duction obtained by cholesterol-lowering agents [24, 25].
num-containing phosphate binders is constrained by the Nevertheless, alternatives to HMG-CoA reductase in-
side effects associated with the absorption of calcium hibitors may be advisable, given the increased risk of
and aluminum. Aluminum absorption can lead to toxicity drug-related side effects in patients with chronic renal
failure [18]. In addition, sevelamer treatment signifi-in some patients [8–13], and calcium carbonate or cal-
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9. Kaye M: Oral aluminium toxicity in a nondialized patient withcantly increases HDL-cholesterol [16], or has no effect
renal failure. Clin Nephrol 20:208–211, 1983
at all [7, 18, 19]. The relative benefits of modifying the 10. Malluche HH, Smith AJ, Abreo K, Faugere M-C: The use of
deferoxamine in the management of aluminum accumulation inlipid profile in hemodialysis patients are also unknown.
bone in patients with renal failure. N Engl J Med 311:140–144,Levels of serum cholesterol at both extremes were associ- 1984
ated with an increased risk of death in a large cohort of 11. Hodsman AB, Sherrard DJ, Alfrey AC, et al: Bone aluminium
and histomorphometric features of renal osteodystrophy. J Clinhemodialysis patients [16, 18, 26]. Currently, atheroescl-
Endocrinol Metab 54:539–546, 1982
erosis is accelerated by as much as 20 years in dialysis 12. Cannata JB, Olaizola IR, Gomez C, et al: Serum aluminum
transport and aluminum uptake in crhonic renal failure: Role ofpatients compared to the general population [27], and the
iron and aluminum metabolism. Nephron 65:141–146, 1993risk of myocardial ischemia and infarction is increased in 13. Cannata JB, Fernandez I, Fernandez MJ, Fernandez JL: Role
patients with ESRD, compared with nonuremic age- and of iron metabolism in absorption and cellular uptake of aluminum.
Kidney Int 39:799–803, 1991sex-matched individuals [28]. Changes in LDL-choles-
14. Delmez J, Slatopolsky E: Hyperphosphatemia: Its consequences
terol and HDL-cholesterol induced by sevelamer in this and treatment in patients with chronic renal disease. Am J Kidney
Dis 4:303–317, 1992study would be expected to reduce the rate of cardiovas-
15. Hercz G, Kraut JA, Andress DA, et al: Use of calcium carbonatecular disease, and potentially increase survival in these as a phosphate binder in dialysis patients. Miner Electrolyte Metab
patients. Whether there might be an additive or synergic 12:314–319, 1986
16. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long termeffect of modifying the lipid profile and lowering calcium
effects of sevelamer hydrochloride on the calcium x phosphatex phosphate product is still unknown [16]. profile on haemodialysis patients. Nephrol Dial Transplant 14:2907–
2914, 1999
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